U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unequivocal Progression

MedGen UID:
474558
•Concept ID:
C3272925
•
Pathologic Function

Definition

An overall level of substantial worsening in non-target disease that is of a magnitude that, even in the presence of SD or PR in target disease, the treating physician would feel it important to change therapy. (RECIST) [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnequivocal Progression

Professional guidelines

PubMed

Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.
O JH, Lodge MA, Wahl RL
Radiology 2016 Aug;280(2):576-84. Epub 2016 Feb 24 doi: 10.1148/radiol.2016142043. PMID: 26909647Free PMC Article
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Litière S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee
Eur J Cancer 2014 Jul;50(10):1847-1853. Epub 2014 Apr 10 doi: 10.1016/j.ejca.2014.03.014. PMID: 24726734
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
Eur J Cancer 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774

Recent clinical studies

Etiology

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X
J Ovarian Res 2021 May 17;14(1):68. doi: 10.1186/s13048-021-00803-2. PMID: 33993885Free PMC Article
Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer.
Fujiwara M, Hayashi T, Takeda H, Yuasa T, Komai Y, Numao N, Yamamoto S, Fukui I, Kouno T, Yonese J
Clin Genitourin Cancer 2021 Feb;19(1):e6-e11. Epub 2020 Jun 2 doi: 10.1016/j.clgc.2020.05.014. PMID: 32636079
Real-world data on nivolumab treatment of non-small cell lung cancer.
Brustugun OT, Sprauten M, Helland Å
Acta Oncol 2017 Mar;56(3):438-440. Epub 2016 Nov 28 doi: 10.1080/0284186X.2016.1253865. PMID: 27892773
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
Eur J Cancer 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.
Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L
Hepatology 2005 Jan;41(1):82-7. doi: 10.1002/hep.20519. PMID: 15690484

Diagnosis

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X
J Ovarian Res 2021 May 17;14(1):68. doi: 10.1186/s13048-021-00803-2. PMID: 33993885Free PMC Article
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Litière S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee
Eur J Cancer 2014 Jul;50(10):1847-1853. Epub 2014 Apr 10 doi: 10.1016/j.ejca.2014.03.014. PMID: 24726734
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M
Cancer 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406. PMID: 19514084
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M
J Clin Oncol 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. PMID: 18445844
Cervical spondylosis: natural history and rare indications for surgical decompression.
Hunt WE
Clin Neurosurg 1980;27:466-80. doi: 10.1093/neurosurgery/27.cn_suppl_1.466. PMID: 7273568

Therapy

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X
J Ovarian Res 2021 May 17;14(1):68. doi: 10.1186/s13048-021-00803-2. PMID: 33993885Free PMC Article
Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer.
Fujiwara M, Hayashi T, Takeda H, Yuasa T, Komai Y, Numao N, Yamamoto S, Fukui I, Kouno T, Yonese J
Clin Genitourin Cancer 2021 Feb;19(1):e6-e11. Epub 2020 Jun 2 doi: 10.1016/j.clgc.2020.05.014. PMID: 32636079
Real-world data on nivolumab treatment of non-small cell lung cancer.
Brustugun OT, Sprauten M, Helland Å
Acta Oncol 2017 Mar;56(3):438-440. Epub 2016 Nov 28 doi: 10.1080/0284186X.2016.1253865. PMID: 27892773
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M
Cancer 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406. PMID: 19514084
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
Eur J Cancer 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774

Prognosis

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group
J Clin Oncol 2019 May 1;37(13):1102-1110. Epub 2019 Mar 12 doi: 10.1200/JCO.18.01100. PMID: 30860949Free PMC Article
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Litière S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee
Eur J Cancer 2014 Jul;50(10):1847-1853. Epub 2014 Apr 10 doi: 10.1016/j.ejca.2014.03.014. PMID: 24726734
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
J Natl Cancer Inst 2013 May 1;105(9):654-63. Epub 2013 Feb 19 doi: 10.1093/jnci/djt026. PMID: 23425564Free PMC Article
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M
Cancer 2009 Aug 1;115(15):3512-8. doi: 10.1002/cncr.24406. PMID: 19514084
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.
Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L
Hepatology 2005 Jan;41(1):82-7. doi: 10.1002/hep.20519. PMID: 15690484

Clinical prediction guides

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X
J Ovarian Res 2021 May 17;14(1):68. doi: 10.1186/s13048-021-00803-2. PMID: 33993885Free PMC Article
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group
J Clin Oncol 2019 May 1;37(13):1102-1110. Epub 2019 Mar 12 doi: 10.1200/JCO.18.01100. PMID: 30860949Free PMC Article
Real-world data on nivolumab treatment of non-small cell lung cancer.
Brustugun OT, Sprauten M, Helland Å
Acta Oncol 2017 Mar;56(3):438-440. Epub 2016 Nov 28 doi: 10.1080/0284186X.2016.1253865. PMID: 27892773
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Litière S, de Vries EGE, Seymour L, Sargent D, Shankar L, Bogaerts J; RECIST Committee
Eur J Cancer 2014 Jul;50(10):1847-1853. Epub 2014 Apr 10 doi: 10.1016/j.ejca.2014.03.014. PMID: 24726734
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.
Fartoux L, Chazouillères O, Wendum D, Poupon R, Serfaty L
Hepatology 2005 Jan;41(1):82-7. doi: 10.1002/hep.20519. PMID: 15690484

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...